Summary:
- The article examines Bristol Myers Squibb’s (BMS) strategic pivot toward neuroscience, tracing the company's current R&D capabilities back to the integration of assets acquired during the $74 billion Celgene merger.
- It highlights the development of key therapeutic candidates, such as the schizophrenia drug Cobenfy (formerly KarXT), illustrating how BMS utilized a combination of internal research, strategic acquisitions, and robust clinical trial data to revitalize its focus on complex neurological disorders.